Drug discovery for the developing world: Progress at the Novartis Institute for Tropical Diseases

Nature Reviews Drug Discovery

Volumn 14, Issue 6, 2015, Pages 442-444

  Jones, Catherine L ^a   Yeung, Bryan K S ^b   Manjunatha, Ujjini ^b   Shi, Pei Yong ^b   Bodenreider, Christophe ^b   Diagana, Thierry T ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIVIRUS AGENT; ARTEMISININ; ARTESUNATE; CHLOROQUINE; CIPARGAMIN; ENDOPEPTIDASE CLP; FIDAXOMICIN; GLYCEROL; HELICASE; IMIDAZOLECARBOXAMIDE; IMIDAZOPYRIDINE DERIVATIVE; ISONIAZID; KAF 156; KAI 407; MEFLOQUINE; METHYLTRANSFERASE; NITD 008; NITD 304; NITD 349; NITD 916; PRIMAQUINE; PROTEINASE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; S ADENOSYLMETHIONINE; SODIUM CHANNEL; TUBERCULOSTATIC AGENT; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC SENSITIVITY; CHANNEL GATING; DENGUE; DENGUE VIRUS; DISEASE COURSE; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IN VITRO STUDY; INTERNATIONAL COOPERATION; LETTER; LICENCE; LIVER CELL CULTURE; MALARIA; MEDICAL EXPERT; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM BERGHEI INFECTION; PLASMODIUM CYNOMOLGI; PLASMODIUM VIVAX; PLASMODIUM YOELII; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; SINGAPORE; SPOROZOITE; TROPICAL DISEASE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; DEVELOPING COUNTRY; DRUG DEVELOPMENT; ECONOMICS; ORGANIZATION; TRENDS; TROPICAL MEDICINE;

ACADEMIES AND INSTITUTES; DEVELOPING COUNTRIES; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; TROPICAL MEDICINE;

EID: 84930333856     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4001-c1     Document Type: Letter

References (21)

1. Zumla A., Nahid P. & Cole S. T. Advances in the development of new tuberculosis drugs and treatment regimens. Nature Rev. Drug Discov. 12, 388-404 (2013
2. Dembele L., et al. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS ONE 6, e18162 (2011
3. Zeeman A. M., et al. KAI407, a potent non 8 aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Antimicrob. Agents Chemother. 58, 1586-1595 (2014
4. Schul W., Liu W., Xu H. Y., Flamand M. & Vasudevan S. G. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195, 665-674 (2007
5. Yin Z., et al. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl Acad. Sci. USA 106, 20435-20439 (2009
6. Erbel P., et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nature Struct. Mol. Biol. 13, 372-373 (2006
7. Noble C. G., Seh C. C., Chao A. T. & Shi P. Y. Ligand-bound structures of the dengue virus protease reveal the active conformation. J. Virol. 86, 438-446 (2012
8. Lim S. P., et al. Small molecule inhibitors that selectively block dengue virus methyltransferase. J. Biol. Chem. 286, 6233-6240 (2011
9. Yap T. L., et al. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85Å resolution. J. Virol. 81, 4753-4765 (2007
10. Xu T., et al. Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 Å. J. Virol. 79, 10278-10288 (2005
11. Rottmann M., et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180 (2010
12. Spillman N. J., et al. Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13, 227-237 (2011
13. White N. J., et al. Spiroindolone KAE609 for falciparum and vivax malaria. N. Engl. J. Med. 371, 403-410 (2014
14. Meister S., et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372-1377 (2011
15. Kuhen K. L., et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob. Agents Chemother. 58, 5060-5067 (2014
16. McNamara C. W., et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504, 248-253 (2013
17. Pethe K., et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nature Commun. 1, 57 (2010
18. Pethe K., et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nature Med. 19, 1157-1160 (2013
19. Yokokawa F., et al. Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents. ACS Med. Chem. Lett. 4, 451-455 (2013
20. Rao S. P., et al. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci. Transl Med. 5, 214ra168 (2013
21. Manjunatha U. H., et al. Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci. Transl Med. 7, 269ra263 (2015